Universal fibronectin type III binding-domain libraries

• US 8,697,608 B2
• Filed: 08/04/2010
• Issued: 04/15/2014
• Est. Priority Date: 08/10/2007
• Status: Active Grant

• Current Assignee: Protelica Inc.
• Original Assignee: Protelica Inc.
• Inventors: Cappuccilli, Guido, Crea, Roberto, Shen, Randy, Hokanson, Craig A., Kirk, Peter B., Liston, David R.
• Primary Examiner(s): BOESEN, CHRISTIAN C
• Application Number:
  US12/850,219
• Publication Number:
  US 20110124527A1
• Time in Patent Office: 1,350 Days
• Field of Search: None
• US Class Current: 506/26
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 16/241 Tumor Necrosis Factors
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype
• CPC Class Codes: C07K 2318/20 Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
• CPC Class Codes: C07K 2319/30 Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
• CPC Class Codes: C12N 15/1044 Preparation or screening of libraries displayed on scaffold proteins

Abstract

Walk-through mutagenesis and natural-variant combinatorial fibronectin Type III (FN3) polypeptide libraries are described, along with their method of construction and use. Also disclosed are a number of high binding affinity polypeptides selected by screening the libraries against a variety of selected antigens.

Claims

1. A method of forming a library of fibronectin Type 3 (FN3) domain polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity, comprising

(i) aligning BC, DE, and FG amino acid loop sequences in a collection of native fibronectin Type 3 domain polypeptides,

(ii) segregating the aligned loop sequences according to loop length,

(iii) for a selected loop and loop length from step (ii), performing positional amino acid frequency analysis to determine the frequencies of amino acids at each loop position,

(iv) for each loop and loop length analyzed in step (iii), identifying at each position a conserved or selected semi-conserved consensus amino acid and other natural-variant amino acids,

(v) for at least one selected loop and loop length, forming:

(1) a library of walk-through mutagenesis sequences expressed by a library of coding sequences that encode, at each loop position, the consensus amino acid, and if the consensus amino acid has an occurrence frequency equal to or less than a selected threshold frequency of at least 50%, a single common target amino acid and any co-produced amino acids, or

(2) a library of natural-variant combinatorial sequences expressed by a library of coding sequences that encode at each loop position, a consensus amino acid and, if the consensus amino acid has a frequency of occurrence equal to or less than a selected threshold frequency of at least 50%, other natural variant amino acids, including semi-conserved amino acids and variable amino acids whose occurrence rate is above a selected minimum threshold occurrence at that position, or their chemical equivalents,

(vi) incorporating the library of coding sequences into framework FN3 coding sequences to form an FN3 expression library, and

(vii) expressing the FN3 polypeptides of the expression library, wherein all of the amino acids in the beta-strand regions A, AB, B, C, CD, D, E, EF, F, and G of said expressed FN3 polypeptides are the wildtype amino acid sequences of the 14th fibronectin Type III module of human fibronectin.

2. The method of claim 1, wherein the given threshold frequency is a selected frequency between 50-95%.

3. The method of claim 1, wherein step (ii) segregates the loops and loop lengths into the group consisting of BC/11, BC/14, BC/15, DE/6, FG/8, and FG/11.

4. The method of claim 1, wherein the library formed has a library of walk-through mutagenesis sequences formed at each of the loops and loop lengths selected from the group consisting of BC/11, BC/14, BC/15, DE/6, FG/8, and FG11, and from each of the common target amino acid selected from the group consisting of lysine, glutamine, aspartic acid, tyrosine, leucine, praline, serine, histidine, and glycine.

5. The method of claim 1, wherein the library formed has a library of natural-variant combinatorial sequences at a combination of loops and loop lengths selected from loops BC and DE, BC and FG, and DE and FG loops, where the BC loop is selected from one of BC/11, BC/14, and BC/15, the DE loop is DE/6, and the FG loop is selected from one of FG/8, and FG11.

6. The method of claim 5, wherein the given threshold is 100%, unless the loop amino acid position contains only one dominant and one variant amino acid, and the dominant and variant amino acid have side chains with similar physiochemical properties, in which case the given threshold is 90%.

7. The method of claim 5, wherein the two loops in the selected combination of loops and loop lengths has an average diversity of between 10⁵ and 10⁷, or where the average number of different amino acids at each position is equal to or less than 5.